CRSP vs COGT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CRSP · CRISPR Therapeutics$50.07 ▲ 3.11%
COGT · Cogent Biosciences$31.65 ▲ 6.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CRSP -8.3%
- COGT -2.5%
Head to head
| Metric | CRSP | COGT |
|---|---|---|
| Price | $50.07 | $31.65 |
| Change today | ▲ 3.11% | ▲ 6.98% |
| Market cap | $4.86B | $5.49B |
| Return, 3 months | -6.4% | -23.8% |
| Return, year to date | -4.5% | -10.9% |
| Return, 1 year | -9.2% | +113.5% |
| P/E (TTM) | – | – |
| P/B | 2.9 | 12.2 |
| P/E percentile vs own 5y | 35th | 18th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +1,041.4% | – |
| Net profit growth (YoY) | +56.3% | -31.1% |
| Gross margin | -1,691.3% | – |
| Operating margin | -4,857.6% | – |
| Net margin | -4,101.3% | – |
| Return on equity | -26.1% | -146.5% |
| Analyst target vs. price | +46.9% | +73.4% |
| Analyst buy share | 58% | 89% |
| RSI (14) | 46 | 52 |
| 30-day volatility | 52.6% | 47.6% |
| Max drawdown, 1 year | -32.5% | -34.4% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- COGT is the largest of the group by market value.
- COGT has returned the most over the past year.
- COGT has been the calmest stock over the last 30 days.